ISSN 0564-3783  

Main page
Information to authors
Editorial board
Mobile version

In Ukrainian

Export citations

Direct and an indirect effect of liposomal miR-101 on cellular model of alzheimer’s disease

Sokolik V.V., Berchenko O.G., Kolyada O.K., Shulga S.M.


SUMMARY. At present, brain diseases are an unsolved problem of the 21st century. Alzheimer’s disease was first discovered 100 years ago, and during this time not a single patient with this diagnosis has been cured. Therefore, the search for new treatment strategies using regulatory agents such as specific miRNAs is urgent. The aim was to determine the effect of liposomal miR-101 on amyloid-β protein 42 (Aβ42) levels and the cytokine system in a cellular model of Alzheimer’s disease. The work included PCR, ELISA and fluorescent methods. Using FAM, it was found that liposomal miR-101 accumulates in blood mononuclear cells pretreated with Aβ40 aggregates and functions for 2–3 hours, rather than being instantly destroyed by nucleases. Exogenous miR-101 did not affect AβPP gene transcription and decreased the formation of endogenous Aβ42. An indirect anti-inflammatory effect of liposomal miR-101 was established after 12 hours of incubation with mononuclear cells: a decrease in intracellular levels of TNFα and IL-10. However, miRNA-101 did not affect the expression of TNFα and IL-6 and delayed the peak of activation of IL-10 expression by 9 hours. Thus, liposomal miR-101 showed a direct anti-amyloidogenic effect and an indirect anti-inflammatory effect in a cellular model of Alzheimer’s disease.

Key words: miR-101, Alzheimer's disease, liposomes, β-amyloid peptide, cytokines, blood mononuclear cells, fluorescein

Tsitologiya i Genetika 2021, vol. 55, no. 6, pp. 3-14

  1. SI «Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Sciences of Ukraine», 46, Akademika Pavlova str., Kharkiv, Ukraine, 61000
  2. SI «D.F. Chebotaryov Institute of Gerontology of National Academy of Medical Sciences of Ukraine», 67, Vyshgorodskaya str., Kyiv, Ukraine, 04114
  3. SI «Institute of Food Biotechnology and Genomics of National Academy of Sciences of Ukraine», 2a, Osypovskoho str., Kyiv, Ukraine, 04123

E-mail: Shulga5, v.sokolik67, berchenko.olga, alex.genetic

Sokolik V.V., Berchenko O.G., Kolyada O.K., Shulga S.M. Direct and an indirect effect of liposomal miR-101 on cellular model of alzheimer’s disease, Tsitol Genet., 2021, vol. 55, no. 6, pp. 3-14.

In "Cytology and Genetics":
V. V. Sokolik, O. H. Berchenko, O. K. Kolyada & S. M. Shulga Direct and Indirect Action of Liposomal Form of MIR-101 on Cells in the Experimental Model of Alzheimer’s Disease, Cytol Genet., 2021, vol. 55, no. 6, pp. 499–509
DOI: 10.3103/S009545272106014


1. Agostini, M., Tucci, P., Killick, R., et al., Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets, Proc. Natl. Acad. Sci. U. S. A., 2011.

2. Amakiri, N., Kubosumi, A., Tran, J., et al., Amyloid beta and microRNAs in Alzheimer’s disease, Front. Neurosci., 2019.

3. Arancibia, S., Silhol, M., Mouliere, F., et al., Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats, Neurobiol. Dis., 2008.

4. Barak, B., Shvarts-Serebro, I., Modai, S., et al., Opposing actions of environmental enrichment and Alzheimer’s disease on the expression of hippocampal microRNAs in mouse models, Transl. Psychiatry, 2013.

5. Bertram, L., McQueen, M.B., Mullin, K., et al., Systematic meta-analyses of Alzheimer disease genetic association studies: the alzgene database, Nat. Genet., 2007.

6. Boissonneault, V., Plante, I., Rivest, S., et al., MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1, J. Biol. Chem., 2009.

7. Brouwers, N., Sleegers, K., Engelborghs, S., et al., Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer’s disease, Brain, 2006.

8. Chakrabarty, A., Tranguch, S., Daikoku, T., et al., MicroRNA regulation of cyclooxygenase-2 during embryo implantation, Proc. Natl. Acad. Sci. U. S. A., 2007.

9. Czauderna, F., Fechtner, M., Dames, S., et al., Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells, Nucleic Acids Res., 2003.

10. Delay, C., Mandemakers, W., and Hebert, S.S., MicroRNAs in Alzheimer’s disease, Neurobiol. Dis., 2012.

11. Fenske, D.B., Chonn, A., and Cullis, P.R., Liposomal nanomedicines: an emerging field, Toxicol. Pathol., 2008.

12. Fillit, H., Ding, W.H., Buee, L., et al., Elevated circulating tumor necrosis factor levels in Alzheimer’s disease, Neurosci. Lett., 1991.

13. Frozza, R.L., Lourenco, M.V., and De Felice, F.G., Challenges for Alzheimer’s disease therapy: insights from novel mechanisms beyond memory defects, Front. Neurosci., 2018.

14. Fu, Y., Chen, J., and Huang, Z., Recent progress in microRNA-based delivery systems for the treatment of human disease, ExRNA, 2019.

15. Griffin, W.S., Nicoll, J.A., Grimaldi, L.M., et al., The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk, Exp. Gerontol., 2000.

16. Hebert, S.S., Horre, K., Nicolai’, L., et al., Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression, Proc. Natl. Acad. Sci. U. S. A., 2008.

17. Hebert, S.S., Horre, K., Nicolai, L., et al., MicroRNA regulation of Alzheimer’s amyloid precursor protein expression, Neurobiol. Dis., 2009.

18. Kou, X., Chen, D., and Chen, N., The regulation of microRNAs in Alzheimer’s disease, Front. Neurol., 2020.

19. Lee, K., Kim, H., An, K., et al., Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD mouse model of Alzheimer’s disease, Sci. Rep., 2016.

20. Lin, Q., Chen, J., Zhang, Zh., et al., Lipid-based nanoparticles in the systemic delivery of siRNA, Nanomedicine, 2008.

21. Long, J.M. and Lahiri, D.K., MicroRNA-101 down-regulates Alzheimer’s amyloid-beta precursor protein levels in human cell cultures and is differentially expressed, Biochem. Biophys. Res. Commun., 2011.

22. Losurdo, M. and Grilli, M., Extracellular vesicles, influential players of intercellular communication within adult neurogenic niches, Int. J. Mol. Sci., 2020.

23. Lukiw, W.J., Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus, Neuroreport, 2007.

24. Lukiw, W.J. and Alexandrov, P.N., Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer’s disease (AD) brain, Mol. Neurobiol., 2012.

25. Ma, T., Sun, X., Sun, S., et al., The study of peripheral blood miR-29a/101 in the diagnosis of Alzheimer’s disease, Chin. J. Behav. Med. Brain Sci., 2016.

26. Patel, N., Hoang, D., Miller, N., et al., MicroRNAs can regulate human APP levels, Mol. Neurodegeneration, 2008.

27. Pillai, R.S., MicroRNA function: multiple mechanisms for a tiny RNA?, RNA, 2005.

28. Rajagopalan, L.E. and Malter, J.S., Growth factor-mediated stabilization of amyloid precursor protein mRNA is mediated by a conserved 29-nucleotide sequence in the 3'-untranslated region, J. Neurochem., 2000.

29. Rajagopalan, L.E., Westmark, C.J., Jarzembowski, J.A., et al., HnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA, Nucleic Acids Res., 1998.

30. Ramser, E.M., Gan, K.J., Decker, H., et al., Amyloid-P oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons, Mol. Biol. Cell, 2013.

31. Reddy, P.H., Tonk, S., Kumar, S., et al., A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer’s disease, Biochem. Biophys. Res. Commun., 2017,

32. Redis, R.S., Calin, S., Yang, Y., et al., Cell-to-cell miRNA transfer: from body homeostasis to therapy, Pharmacol. Ther., 2012.

33. Rodriguez-Ortiz, C.J., Baglietto-Vargas, D., Martinez-Coria, H., et al., Upregulation of miR-181 decreases c-Fos and SIRT-1 in the hippocampus of 3xTg-AD mice, J. Alzheimers Dis., 2014.

34. Rogers, J.T., Leiter, L.M., McPhee, J., et al., Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences, J. Biol. Chem., 1999.

35. Rumble, B., Retallack, R., Hilbich, C., et al., Amyloid a4 protein and its precursor in Down’s syndrome and Alzheimer’s disease, N. Engl. J. Med., 1989.

36. Schipper, H.M., Maes, O.C., Chertkow, H.M., et al., MicroRNA expression in Alzheimer blood mononuclear cells, Gene Regul. Syst. Biol., 2007.

37. Sleegers, K., Brouwers, N., Gijselinck, I., et al., APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy, Brain, 2006.

38. Sokolik, V.V., Berchenko, O.G., Levicheva, N.O., et al., Anti-amyloidogenic effect of MiR-101 in experimental Alzheimer’s disease, Biotechnol. Acta, 2008.

39. Sokolik, V.V., Berchenko, O.G., and Shulga, S.M., Comparative analysis of nasal therapy of curcumin soluble and liposomal forms of rats with model of Alzheimer’s disease, J. Alzheimer’s Dis. Parkinsonism, 2017.

40. Song, J. and Lee, J.E., MiR-155 is involved in Alzheimer’s disease by regulating T lymphocyte function, Front. Aging Neurosci., 2015.

41. Strauss, S., Bauer, J., Ganter, U., et al., Detection of interleukin-6 and alpha 2-macroglobulin immuno-reactivity in cortex and hippocampus of Alzheimer’s disease patients, Lab. Invest., 1992, vol. 66, pp. 223–230.

42. Strillacci, A., Griffoni, C., Sansone, P., et al., MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells, Exp. Cell. Res., 2009.

43. Vilardo, E., Barbato, C., Ciotti, M., et al., MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons, J. Biol. Chem., 2010.

44. Yingchoncharoen, Ph., Kalinowski, D.S., and Richardson, D.R., Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come, Pharmacol. Rev., 2016.

45. Zhang, J., Hu, M., Teng, Z., et al., Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer’s disease, J. Neurosci., 2014.

Copyright© ICBGE 2002-2023 Coded & Designed by Volodymyr Duplij Modified 03.10.23